All News

Breast cancer survivors may experience medium to high symptom burden five or more years after receiving a diagnosis, according to a recent study.

I had the wrong interpretation of what a cancer survivor was. That was until I was diagnosed with a rare cancer and shockingly, the term “cancer survivor” became a part of my journey.

Balversa improved outcomes for patients with high-risk bladder cancer, but may only work for those with a certain genetic alteration, an expert explained.

After the fear of my cancer diagnosis subsided, I decided to swing at it with all my strength.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to demonstrate makeup techniques in applying foundation and blush to combat appearance-related side effect from cancer treatment.

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Excellent adherence to hormonal therapy among patients with ductal carcinoma in situ plays a key role in reducing risk of future tumors, researchers found.

In a recent study, obesity was linked to an increased risk of recurrence for patients with HR-positive, early-stage breast cancer.

Braving the storm that is cancer.

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss skincare during cancer treatment to assist patients in their daily routine.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss eyebrow shaping techniques and applying eye shadow and mascara to address appearance-related effect from cancer treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss lip care as part of one’s makeup routine to address appearance-related effects from cancer.

Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.

Cancer forced me to face my mortality — and in doing so, I crafted a bucket list and embraced the true meaning of life.

Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, explains why the approval of Braftovi and Mektovi “It's an important improvement in our armamentarium.”

The Food and Drug Administration approved Tibsovo for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation.

One expert explains why palliative care for patients with cancer “is about aligning the patient's goals and the family's goals with the therapeutic goals.”

I had to redefine the relationship with my mother during the most challenging of times.

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.

Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.

Some topics are difficult to talk about. This is one of them.

There are limits and adaptations that are needed during childhood, adulthood and retirement, and I can say the same for every step of my cancer experience.

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.

For the first time, a drug combination (Padcev plus Keytruda) outperformed frontline chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.